These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 33420915)
21. In vitro and in vivo comparative study of a novel Chen H; Cai P; Feng Y; Sun Z; Wang Y; Chen Y; Zhang W; Liu N; Zhou Z Sci Rep; 2021 Sep; 11(1):19122. PubMed ID: 34580375 [No Abstract] [Full Text] [Related]
23. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer. Robu S; Schottelius M; Eiber M; Maurer T; Gschwend J; Schwaiger M; Wester HJ J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024 [TBL] [Abstract][Full Text] [Related]
24. Effects of Linker Modification on Tumor-to-Kidney Contrast of Kuo HT; Pan J; Zhang Z; Lau J; Merkens H; Zhang C; Colpo N; Lin KS; Bénard F Mol Pharm; 2018 Aug; 15(8):3502-3511. PubMed ID: 29920108 [No Abstract] [Full Text] [Related]
25. Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer. Vázquez SM; Endepols H; Fischer T; Tawadros SG; Hohberg M; Zimmermanns B; Dietlein F; Neumaier B; Drzezga A; Dietlein M; Schomäcker K Mol Imaging Biol; 2022 Feb; 24(1):115-125. PubMed ID: 34370181 [TBL] [Abstract][Full Text] [Related]
26. Nelson BJB; Leier S; Wilson J; Wuest M; Doupe J; Andersson JD; Wuest F Nucl Med Biol; 2024; 128-129():108875. PubMed ID: 38199184 [TBL] [Abstract][Full Text] [Related]
27. PSMA-D4 Radioligand for Targeted Therapy of Prostate Cancer: Synthesis, Characteristics and Preliminary Assessment of Biological Properties. Garnuszek P; Karczmarczyk U; Maurin M; Sikora A; Zaborniak J; Pijarowska-Kruszyna J; Jaroń A; Wyczółkowska M; Wojdowska W; Pawlak D; Lipiński PFJ; Mikołajczak R Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800517 [TBL] [Abstract][Full Text] [Related]
28. Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals. Wüstemann T; Bauder-Wüst U; Schäfer M; Eder M; Benesova M; Leotta K; Kratochwil C; Haberkorn U; Kopka K; Mier W Theranostics; 2016; 6(8):1085-95. PubMed ID: 27279903 [TBL] [Abstract][Full Text] [Related]
29. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile. Benešová M; Umbricht CA; Schibli R; Müller C Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475 [TBL] [Abstract][Full Text] [Related]
30. Preparation and Biological Evaluation of [ Xiao D; Duan X; Gan Q; Zhang X; Zhang J Molecules; 2020 Nov; 25(23):. PubMed ID: 33256058 [TBL] [Abstract][Full Text] [Related]
31. Preclinical Evaluation and Pilot Clinical Study of Al Liu T; Liu C; Xu X; Liu F; Guo X; Li N; Wang X; Yang J; Yang X; Zhu H; Yang Z J Nucl Med; 2019 Sep; 60(9):1284-1292. PubMed ID: 30796170 [TBL] [Abstract][Full Text] [Related]
33. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. Lapi SE; Wahnishe H; Pham D; Wu LY; Nedrow-Byers JR; Liu T; Vejdani K; VanBrocklin HF; Berkman CE; Jones EF J Nucl Med; 2009 Dec; 50(12):2042-8. PubMed ID: 19910433 [TBL] [Abstract][Full Text] [Related]
34. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
35. Gallium-68 and scandium-44 labelled radiotracers based on curcumin structure linked to bifunctional chelators: Synthesis and characterization of potential PET radiotracers. Orteca G; Sinnes JP; Rubagotti S; Iori M; Capponi PC; Piel M; Rösch F; Ferrari E; Asti M J Inorg Biochem; 2020 Mar; 204():110954. PubMed ID: 31838188 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of Bobba KN; Bidkar AP; Meher N; Fong C; Wadhwa A; Dhrona S; Sorlin A; Bidlingmaier S; Shuere B; He J; Wilson DM; Liu B; Seo Y; VanBrocklin HF; Flavell RR J Nucl Med; 2023 Jul; 64(7):1076-1082. PubMed ID: 37201957 [No Abstract] [Full Text] [Related]
38. Clinical translation of a PSMA inhibitor for Ferro-Flores G; Luna-Gutiérrez M; Ocampo-García B; Santos-Cuevas C; Azorín-Vega E; Jiménez-Mancilla N; Orocio-Rodríguez E; Davanzo J; García-Pérez FO Nucl Med Biol; 2017 May; 48():36-44. PubMed ID: 28193503 [TBL] [Abstract][Full Text] [Related]
39. Synthesis and preclinical evaluation of the 177Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancer. Escudero-Castellanos A; Ocampo-García B; Ferro-Flores G; Santos-Cuevas C; Morales-Ávila E; Luna-Gutiérrez M; Isaac-Olivé K Nucl Med Commun; 2019 Mar; 40(3):278-286. PubMed ID: 30763290 [TBL] [Abstract][Full Text] [Related]
40. Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. Lesche R; Kettschau G; Gromov AV; Böhnke N; Borkowski S; Mönning U; Hegele-Hartung C; Döhr O; Dinkelborg LM; Graham K Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):89-101. PubMed ID: 23955632 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]